Brian E. Nolan
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Brian E. Nolan.
Journal of Virology | 2008
Victoria Kasprowicz; Julian Schulze zur Wiesch; Thomas Kuntzen; Brian E. Nolan; Steven Longworth; Andrew Berical; Jenna Blum; Cory McMahon; Laura L. Reyor; Nahel Elias; William W. Kwok; Barbara G. McGovern; Gordon J. Freeman; Raymond T. Chung; Paul Klenerman; Lia Laura Lewis-Ximenez; Bruce D. Walker; Todd M. Allen; Arthur Y. Kim; Georg M. Lauer
ABSTRACT We monitored expression of PD-1 (a mediator of T-cell exhaustion and viral persistence) on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells from blood and liver during acute and chronic infections and after the resolved infection stage. PD-1 expression on HCV-specific T cells was high early in acute infection irrespective of clinical outcome, and most cells continued to express PD-1 in resolved and chronic stages of infection; intrahepatic expression levels were especially high. Our results suggest that an analysis of PD-1 expression alone is not sufficient to predict infection outcome or to determine T-cell functionality in HCV infection.
Journal of Experimental Medicine | 2012
Julian Schulze zur Wiesch; Donatella Ciuffreda; Lia Laura Lewis-Ximenez; Victoria Kasprowicz; Brian E. Nolan; Hendrik Streeck; Jasneet Aneja; Laura L. Reyor; Todd M. Allen; Ansgar W. Lohse; Barbara H. McGovern; Raymond T. Chung; William W. Kwok; Arthur Y. Kim; Georg M. Lauer
Early after symptom onset, HCV-specific CD4+ T cell responses are primed and detectable in patients regardless of clinical outcome, but without early antiviral therapy these T cells become exhausted or deleted in chronically infected patients.
Gastroenterology | 2011
Arthur Y. Kim; Thomas Kuntzen; Joerg Timm; Brian E. Nolan; Melanie A. Baca; Laura L. Reyor; Andrew Berical; Andrea J. Feller; Kristin Johnson; Julian Schulze zur Wiesch; Gregory K. Robbins; Raymond T. Chung; Bruce D. Walker; Mary Carrington; Todd M. Allen; Georg M. Lauer
BACKGROUND & AIMS HLA class I alleles are linked to spontaneous control of hepatitis C virus (HCV) and human immunodeficiency virus-1, but for HCV the roles of particular alleles and corresponding CD8(+) T-cell responses remain incompletely defined. We aimed to determine the correlations between these alleles and natural outcomes of HCV and determine associated key T-cell responses. METHODS In a cohort of HCV individuals, we determined HLA class I alleles, HCV outcomes, T-cell responses, and examined sequence data for mutational changes within key epitopes. RESULTS Carriage of HLA-B 57 was associated with a higher rate of viral clearance (risk ratio = 2.0; 95% confidence interval: 1.2-3.4), while HLA-B 08 was associated with a lower rate (risk ratio = 0.34; 95% confidence interval: 0.1-0.9]. Two HLA-B 57-restricted T-cell epitopes were targeted in spontaneous clearance; subjects with chronic viremia expressing HLA-B 57 harbored HCV strains with a high frequency of mutations in key residues. HLA-B 57-mediated escape was supported by diminished immune recognition of these variants and acute HCV infection revealing viral evolution toward less recognized variants. Analysis of a genotype 1b strain from a single-source HCV outbreak in which HLA-B 57 was not protective revealed sequence variations that interfere with immunogenicity, thereby preventing HLA-B 57-mediated immune pressure. CONCLUSIONS Our data indicate a role of HLA-B 57-restricted CD8(+) T-cell responses in mediating spontaneous clearance and evolution in HCV infection, and viral strains containing epitope variants that are less recognized abrogate the protective effects of HLA-B 57. The finding that HLA-B 57-mediated antiviral immunity is associated with control of both human immunodeficiency virus-1 and HCV suggests a common shared mechanism of a successful immune response against persistent viruses.
Hepatology | 2007
Joerg Timm; Bin Li; Marcus Daniels; Tanmoy Bhattacharya; Laura L. Reyor; Rachel L. Allgaier; Thomas Kuntzen; Will Fischer; Brian E. Nolan; Jared E. Duncan; Julian Schulze zur Wiesch; Arthur Y. Kim; Nicole Frahm; Christian Brander; Raymond T. Chung; Georg M. Lauer; Bette T. Korber; Todd M. Allen
CD8+ T cell responses play a key role in governing the outcome of hepatitis C virus (HCV) infection, and viral evolution enabling escape from these responses may contribute to the inability to resolve infection. To more comprehensively examine the extent of CD8 escape and adaptation of HCV to human leukocyte antigen (HLA) class I restricted immune pressures on a population level, we sequenced all non‐structural proteins in a cohort of 70 chronic HCV genotype 1a‐infected subjects (28 subjects with HCV monoinfection and 42 with HCV/human immunodeficiency virus [HIV] coinfection). Linking of sequence polymorphisms with HLA allele expression revealed numerous HLA‐associated polymorphisms across the HCV proteome. Multiple associations resided within relatively conserved regions, highlighting attractive targets for vaccination. Additional mutations provided evidence of HLA‐driven fixation of sequence polymorphisms, suggesting potential loss of some CD8 targets from the population. In a subgroup analysis of mono‐ and co‐infected subjects some associations lost significance partly due to reduced power of the utilized statistics. A phylogenetic analysis of the data revealed the substantial influence of founder effects upon viral evolution and HLA associations, cautioning against simple statistical approaches to examine the influence of host genetics upon sequence evolution of highly variable pathogens. Conclusion: These data provide insight into the frequency and reproducibility of viral escape from CD8+ T cell responses in human HCV infection, and clarify the combined influence of multiple forces shaping the sequence diversity of HCV and other highly variable pathogens. (HEPATOLOGY 2007.)
Journal of Virology | 2007
Thomas Kuntzen; Joerg Timm; Andrew Berical; Lia Laura Lewis-Ximenez; Brian E. Nolan; Julian Schulze zur Wiesch; Bin Li; Arne Schneidewind; Arthur Y. Kim; Raymond T. Chung; Georg M. Lauer; Todd M. Allen
ABSTRACT CD8+-T-cell responses play an important role in the containment and clearance of hepatitis C virus (HCV) infection, and an association between viral persistence and development of viral escape mutations has been postulated. While escape from CD8+-T-cell responses has been identified as a major driving force for the evolution of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV), a broader characterization of this relationship is needed in HCV infection. To determine the extent, kinetics, and driving forces of HCV sequence evolution, we sequenced the entire HCV genome longitudinally in four subjects monitored for up to 30 months after acute infection. For two subjects the transmission sources were also available. Of 53 total nonenvelope amino acid substitutions detected, a majority represented forward mutations away from the consensus sequence. In contrast to studies in HIV and SIV, however, only 11% of these were associated with detectable CD8+ T-cell responses. Interestingly, 19% of nonenvelope mutations represented changes toward the consensus sequence, suggesting reversion in the absence of immune pressure upon transmission. Notably, the rate of evolution of forward and reverse mutations correlated with the conservation of each residue, which is indicative of structural constraints influencing the kinetics of viral evolution. Finally, the rate of sequence evolution was observed to decline over the course of infection, possibly reflective of diminishing selection pressure by dysfunctional CD8+ T cells. Taken together, these data provide insight into the extent to which HCV is capable of evading early CD8+ T-cell responses and support the hypothesis that dysfunction of CD8+ T cells may be associated with failure to resolve HCV infections.
Journal of Hepatology | 2011
Galit Alter; Stephanie Jost; Suzannah Rihn; Laura L. Reyor; Brian E. Nolan; Musie Ghebremichael; Ronald J. Bosch; Marcus Altfeld; Georg M. Lauer
BACKGROUND & AIMS While the majority of HCV-infected patients progress to chronic hepatitis, a small fraction of individuals are able to clear the virus. Resolution of infection occurs within the first few weeks to months of infection, suggesting that innate immune functions may be critical for early control. Epidemiologic data support a role for particular NK cell receptor bearing populations in this control, yet the mechanism by which NK cells respond to HCV early in infection is unknown. METHODS Changes in the phenotype and function of NK cells were investigated in a cohort of 43 individuals identified during various stages of HCV infection with different clinical outcomes. RESULTS Acute, chronic, and resolved HCV infections were characterized by an expansion of CD56(neg) NK cells. Furthermore, increased levels of HLA-C-binding KIR(+) NK cells were observed in HCV resolvers, while all stages of HCV infection were associated with reduced percentages of NKG2D(+), NKp30(+), and NKp46(+) NK cells, and a slight increase in the ability of NK cells to respond to target cells bearing the ligands for these receptors. In contrast, NKG2A(+) and CD94(+) NK cells were elevated in acute and chronic HCV infection, but not in resolved infection. Most importantly, in acute infection, lower frequencies of NKp30(+), NKp46(+), CD161(+), and NKG2D(+) NK cells were observed in patients who were subsequently able to clear HCV infection than in those becoming chronically infected. CONCLUSIONS These data implicate particular populations of NK cells in the early control and clearance of HCV infection.
Journal of Virology | 2010
Victoria Kasprowicz; Yu-Hoi Kang; Michaela Lucas; Julian Schulze zur Wiesch; Thomas Kuntzen; Vicki M. Fleming; Brian E. Nolan; Steven Longworth; Andrew Berical; Bertram Bengsch; Robert Thimme; Lia Laura Lewis-Ximenez; Todd M. Allen; Arthur Y. Kim; Paul Klenerman; Georg M. Lauer
ABSTRACT Hepatitis C virus (HCV)-specific CD8+ T cells in persistent HCV infection are low in frequency and paradoxically show a phenotype associated with controlled infections, expressing the memory marker CD127. We addressed to what extent this phenotype is dependent on the presence of cognate antigen. We analyzed virus-specific responses in acute and chronic HCV infections and sequenced autologous virus. We show that CD127 expression is associated with decreased antigenic stimulation after either viral clearance or viral variation. Our data indicate that most CD8 T-cell responses in chronic HCV infection do not target the circulating virus and that the appearance of HCV-specific CD127+ T cells is driven by viral variation.
Journal of Clinical Investigation | 2008
Victoria Kasprowicz; Scott M. Ward; Alison V. Turner; Alexandros Grammatikos; Brian E. Nolan; Lia Laura Lewis-Ximenez; Charles Sharp; Jenny Woodruff; Vicki M. Fleming; Stuart Sims; Bruce D. Walker; Andrew K. Sewell; Georg M. Lauer; Paul Klenerman
Cross-reactivity of murine and recently human CD8(+) T cells between different viral peptides, i.e., heterologous immunity, has been well characterized. However, the directionality and quality of these cross-reactions is critical in determining their biological importance. Herein we analyzed the response of human CD8(+) T cells that recognize both a hepatitis C virus peptide (HCV-NS3) and a peptide derived from the influenza neuraminidase protein (Flu-NA). To detect the cross-reactive CD8(+) T cells, we used peptide-MHC class I complexes (pMHCs) containing a new mutant form of MHC class I able to bind CD8 more strongly than normal MHC class I complexes. T cell responses against HCV-NS3 and Flu-NA peptide were undetectable in normal donors. In contrast, some responses against the Flu-NA peptide were identified in HCV(+) donors who showed strong HCV-NS3-specific reactivity. The Flu-NA peptide was a weak agonist for CD8(+) T cells in HCV(+) individuals on the basis of novel pMHCs and functional assays. These data support the idea of cross-reactivity between the 2 peptides, but indicate that reactivity toward the Flu-NA peptide is highly CD8-dependent and occurs predominantly after priming during HCV infection. Our findings indicate the utility of the novel pMHCs in dissecting cross-reactivity and suggest that cross-reactivity between HCV and influenza is relatively weak. Further studies are needed to relate affinity and functionality of cross-reactive T cells.
The Journal of Infectious Diseases | 2009
Arthur Y. Kim; Joerg Timm; Brian E. Nolan; Laura L. Reyor; Katherine Kane; Andrew Berical; Kimon C. Zachary; Georg M. Lauer; Thomas Kuntzen; Todd M. Allen
The dramatic antiviral activities of drugs that specifically inhibit hepatitis C virus replication can be tempered by baseline mutations that confer resistance. We describe the kinetics of an R155K mutation in hepatitis C virus (HCV) NS3 protease known to confer resistance to specific protease inhibitors in an individual coinfected with human immunodeficiency virus-1 and HCV. Longitudinal sequences revealed changes in the relative frequency with which this variant was observed independent of HCV replication levels, illustrating that this mutation coexists with wild-type strains in vivo in the absence of drugs. The persistence of drug-resistance mutations argues for baseline resistance genotyping at the time therapy is initiated to accurately predict the efficacy of treatment.
Blood | 2007
Julian Schulze zur Wiesch; Georg M. Lauer; Joerg Timm; Thomas Kuntzen; Martin Neukamm; Andrew Berical; Brian E. Nolan; Steve A. Longworth; Victoria Kasprowicz; Cory McMahon; Alysse Wurcel; Ansgar W. Lohse; Lia Laura Lewis-Ximenez; Raymond T. Chung; Arthur Y. Kim; Todd M. Allen; Bruce D. Walker